Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).

Abstract The management of carotid-artery stenosis that has not caused recent symptoms — asymptomatic carotid stenosis — has been controversial. Clinical trials that began more than 30 years ago ...

A 57-year-old woman with a history of subarachnoid hemorrhage was admitted to the hospital because of visual disturbances involving the right visual field, as well as episodes of shaking of the right ...

This feature about a man hospitalized for uncomplicated diverticulitis who is found to have high blood pressure offers a case vignette accompanied by two essays, one supporting watchful waiting and ...

Methods In a double-blind, randomized, placebo-controlled trial conducted at 26 sites in Canada and Australia, we assigned adult patients receiving maintenance hemodialysis to daily supplementation ...

Abstract More than 470,000 patients with kidney failure receive hemodialysis in the United States alone, with worldwide estimates approaching 3 million patients. Mortality from kidney failure remains ...

Approaches to early detection of cancer often seem contentious, but the big-picture view is actually one of remarkable consensus. All major guideline groups recommend the Papanicolaou smear, ...

Background Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and ...

Human epidermal growth factor receptor 2 (HER2)–directed antibody–drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally ...

Supported by Boston Children’s Hospital, which provided institutional support for DNA sequencing and variant analysis for some participants through the Children’s Rare Disease Collaborative, the ...

Methods In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery ...